Mark A. Pearson

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.

Journal: mAbs

Published: December 09, 2024

Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.

Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.

Journal: Molecular cancer therapeutics

Published: May 24, 2024

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.

Journal: Cancer discovery

Published: March 12, 2024

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.

Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.

Journal: bioRxiv : the preprint server for biology

Published: February 07, 2023

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.

Journal: Nature cancer

Published: January 23, 2023

Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.

Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.

Journal: Oncoimmunology

Published: February 14, 2022

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.

Journal: Nature cancer

Published: July 27, 2021

Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes.

Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes.

Journal: Cell reports

Published: May 27, 2021

Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based Methods.

Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based Methods.

Journal: ChemMedChem

Published: October 25, 2020

Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist.

Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist.

Journal: Molecular cancer therapeutics

Published: March 31, 2020

STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers.

STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers.

Journal: Life science alliance

Published: March 31, 2020

Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.

Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 13, 2020

Showing 1-12 of 30

Last Updated: 09/26/2026